First Section: Putative CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort

First Section: Putative CSF biomarkers of Alzheimer’s disease based on the novel concept of generic protein misfolding and proteotoxicity: the PRAMA cohort Liliana Napolitano This is a section of A multidisciplinary approach for the early diagnosis of Alzheimer’s disease and potential therapeutic applications(DOI: 10.36253/979-12-215-0993-9) by Liliana Napolitano Firenze University Press Florence 2026 https://doi.org/10.36253/979-12-215-0993-9.04

Available for academic research purposes

Open Access

Content licence CC BY 4.0

Metadata licence CC0 1.0

This is original content, published for academic research purposes

Digital edition XML powered by Booksflow

This study explores novel Cereborspinal Fluid (CSF) biomarkers for Alzheimer’s Disease (AD) based on the generic failure of the proteostasis network in the PRAMA cohort. Using biophysical methods like Dynamic Light Scattering (DLS) and cellular Ca2+ influx assays, we identified large protein aggregates and proteotoxic species as key indicators of AD. These parameters effectively discriminate AD patients from non-AD controls. Combining these novel biomarkers with classical Aβ and tau markers significantly enhances diagnostic accuracy, providing a more comprehensive profile of the proteome-wide dysfunction in AD.

CSF Biomarkers PRAMA Cohort Protein Aggregates Proteotoxicity Diagnostic Accuracy.

It is available online at https://doi.org/10.36253/979-12-215-0993-9.04